recently, Indian pharmaceutical corporation Venus Remedies Says it won the battle against the French company SCR Pharmatop Between about the production of intravenous paracetamol solution in India (intravenousparacetamol solution) And carried on as long as 10 The year of the patent war.

before, The Indian pharmaceutical company filed a legal complaint, To remove any patent barriers to the production of intravenous paracetamol solutions in India. Venus Remedies The company said in a statement, Because intravenous paracetamol plays a vital role in controlling inflammation and fever, So the revocation of the patent related to the solution is encouraging news for India's healthcare sector in the face of the pandemic.

Venus Remedies The company added, The Indian Patent Office is in 2021 years 6 month 4 Japan made a final decision in favor of the company, And to uphold its earlier revocation SCR Pharmatop The company's Indian patent decision, The reason is that the patent lacks any creative steps that would make it superior to other existing solutions. The president of the aforementioned Indian pharmaceutical company (Saransh Chaudhary) representation: "What we are trying to do is to make sure that we can make generic versions of key drugs like intravenous paracetamol in this country, And make such drugs available to the public at a reasonable price, Especially during a pandemic. "

Early in 2011 years, Venus Remedies The company is the first to SCR Pharmatop A patent involving intravenous paracetamol solution was challenged. The patent is in 2018 Revocation of year. however, SCR Pharmatop The company later appealed to the Delhi High Court and the Intellectual Property Appeals Board (IPAB) An appeal was filed. IPAB The Indian Patent Office was asked to re-examine the case.

After hearing written submissions from both parties, Indian Patent Office in 2021 years 6 month 4 Japan made a point of maintaining its presence 2018 years 12 month 24 A final decision on the revocation of the decision.

(Compiled from economictimes. indiatimes. com)

Reprinted from China Intellectual Property Network   translation: Li Yanqiu　proofread: Liu Peng

disclaimer: This website reprint articles are from the Internet, Does not represent the views of this website or confirm the authenticity of its content. If the source is mislabeled or the copyright of the article is involved, Please contact this website, This website will be corrected in due course, delete, thank you.